William To, OD
Optometrist · San Mateo, CANPI 1952756678
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 37.7% of the total. Reporting peaked in 2021 at $24,787 and has fallen 95.1% since, to $1,216 in 2025. Among optometrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $262.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$31K
- Bausch & Lomb Americas Inc.$21K
- Sight Sciences, Inc.$18K
- Optos, Inc.$4K
- Alcon$3K
- Johnson & Johnson Vision Care, Inc.$2K
- plus $3K from 13 others
What the payments were for
- Consulting fees$22,54627%
- Speaking & faculty fees$39,62548%
- Travel & lodging$7,3499%
- Food & beverage$11,83814%
- Gifts$170%
- Entertainment$1,2522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 83 | $31,118 |
| Bausch & Lomb Americas Inc. | 47 | $21,254 |
| Sight Sciences, Inc. | 16 | $18,299 |
| Optos, Inc. | 24 | $3,751 |
| Alcon | 43 | $3,299 |
| Johnson & Johnson Vision Care, Inc. | 30 | $1,581 |
| Coopervision Inc. | 32 | $1,487 |
| Visioneering Technologies, Inc. | 9 | $450 |
| ABB Con-cise Optical Group LLC | 9 | $248 |
| Topcon Healthcare, Inc. | 2 | $241 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $200 |
| Dompe US, Inc. | 1 | $125 |
| AbbVie(2 entities) | 3 | $117 |
| Plexus Optix, Inc. | 3 | $114 |
| Lombart Brothers, Inc. | 2 | $98 |
| Novartis | 3 | $85 |
| Carl Zeiss Meditec, Inc. | 2 | $74 |
| Optovue, Inc. | 1 | $71 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFUSE$43,488
- TearCare SmartLid$17,711
- TEARCARE(TM) (2.2) SYSTEM KIT$17,711
- ULTRA$3,330
- BIOTRUE ONE DAY$3,206
- BIOTRUE$2,920
- ULTRA MULTIFOCAL TORIC$2,000
- P200TE$1,798
- Precision 1$1,376
- Acuvue$819
- P200DTx$798
- P200T$798
- P200TxE$798
- PANORAMIC OPHTHALMOSCOPE$550
- DAILIES TOTAL1$500
- OCT OPHTHALMOSCOPE$404
- MyDay Contact Lens$369
- TEARCARE SYSTEM$350
- NFC-700$275
- MiSight Contact Lens$227
How this compares
$82,627 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 44 | $21,981 |
| VyzultaLatanoprostene Bunod | 49 | $19,718 |
| XiidraLifitegrast | 20 | $16,405 |
| RestasisCyclosporine | 11 | $9,603 |
| Cyclosporine | 16 | $4,505 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,251 |
| Travoprost | 12 | $1,966 |
| Latanoprost | 103 | $988 |
| Prednisolone Acetate | 17 | $668 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 37 | $498 |
| Timolol Maleate | 25 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $21,254 | $36,12269 claims |
| AbbVieLumigan, Restasis | $117 | $31,58455 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.
Other optometrist in San Mateo
- Steve YoelinNewport Beach$4.1M
- Matthew GellerSpring Valley$3.5M
- Melissa EricksonDavis$522K
- Omid KhodaiLake Forest$499K
- Jason TuSan Diego$351K
- Scott SchachterPismo Beach$312K
- Alicia LauSan Diego$300K
- Vin DangBakersfield$284K
- Steven FerrucciSepulveda$272K
- Katie ChuRosemead$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.